Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types.
Cornet I, Bouvard V, Campo MS, Thomas M, Banks L, Gissmann L, Lamartine J, Sylla BS, Accardi R, Tommasino M.
J Virol. 2012 Feb;86(4):2366-70. Epub 2011 Dec 14.
Related citations
Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.
J Virol. 2011 Oct;85(20):10472-86. Epub 2011 Aug 3.
The human papillomavirus type 16 E5 oncoprotein translocates calpactin I to the perinuclear region.
Krawczyk E, Suprynowicz FA, Hebert JD, Kamonjoh CM, Schlegel R.
J Virol. 2011 Nov;85(21):10968-75. Epub 2011 Aug 17.
High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression.
Reiser J, Hurst J, Voges M, Krauss P, Münch P, Iftner T, Stubenrauch F.
J Virol. 2011 Nov;85(21):11372-80. Epub 2011 Aug 17.
Cutaneous human papillomavirus type 38 E7 regulates actin cytoskeleton structure for increasing cell proliferation through CK2 and the eukaryotic elongation factor 1A.
Yue J, Shukla R, Accardi R, Zanella-Cleon I, Siouda M, Cros MP, Krutovskikh V, Hussain I, Niu Y, Hu S, Becchi M, Jurdic P, Tommasino M, Sylla BS.
J Virol. 2011 Sep;85(17):8477-94. Epub 2011 Jun 22.
NRIP, a novel calmodulin binding protein, activates calcineurin to dephosphorylate human papillomavirus E2 protein.
Chang SW, Tsao YP, Lin CY, Chen SL.
J Virol. 2011 Jul;85(13):6750-63. Epub 2011 May 4.
Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.
Conrady CD, Halford WP, Carr DJ.
J Virol. 2011 Feb;85(4):1625-33. Epub 2010 Dec 8.
Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.
Morello CS, Levinson MS, Kraynyak KA, Spector DH.
J Virol. 2011 Apr;85(7):3461-72. Epub 2011 Jan 26.
Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD.
Tomaic V, Pim D, Thomas M, Massimi P, Myers MP, Banks L.
J Virol. 2011 Apr;85(7):3120-7. Epub 2011 Jan 12.
Growth inhibition of HeLa cells is a conserved feature of high-risk human papillomavirus E8^E2C proteins and can also be achieved by an artificial repressor protein.
Fertey J, Hurst J, Straub E, Schenker A, Iftner T, Stubenrauch F.
J Virol. 2011 Mar;85(6):2918-26. Epub 2010 Dec 29.
Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers.
Lace MJ, Anson JR, Klussmann JP, Wang DH, Smith EM, Haugen TH, Turek LP.
J Virol. 2011 Feb;85(4):1645-54. Epub 2010 Dec 1.
A systematic analysis of human papillomavirus (HPV) E6 PDZ substrates identifies MAGI-1 as a major target of HPV type 16 (HPV-16) and HPV-18 whose loss accompanies disruption of tight junctions.
Kranjec C, Banks L.
J Virol. 2011 Feb;85(4):1757-64. Epub 2010 Dec 1.
Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.
Krawczyk A, Krauss J, Eis-Hübinger AM, Däumer MP, Schwarzenbacher R, Dittmer U, Schneweis KE, Jäger D, Roggendorf M, Arndt MA.
J Virol. 2011 Feb;85(4):1793-803. Epub 2010 Dec 1.
The inhibitory action of P56 on select functions of E1 mediates interferon's effect on human papillomavirus DNA replication.
Saikia P, Fensterl V, Sen GC.
J Virol. 2010 Dec;84(24):13036-9. Epub 2010 Oct 6.
CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV.
Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, Nagamatsu T, Adachi K, Tomio A, Tomio K, Kojima S, Yasugi T, Kozuma S, Taketani Y.
J Virol. 2010 Nov;84(22):11614-23. Epub 2010 Sep 1.
The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification.
Suprynowicz FA, Krawczyk E, Hebert JD, Sudarshan SR, Simic V, Kamonjoh CM, Schlegel R.
J Virol. 2010 Oct;84(20):10619-29. Epub 2010 Aug 4.
Multiple ASF/SF2 sites in the human papillomavirus type 16 (HPV-16) E4-coding region promote splicing to the most commonly used 3'-splice site on the HPV-16 genome.
Somberg M, Schwartz S.
J Virol. 2010 Aug;84(16):8219-30. Epub 2010 Jun 2.
Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs.
Iversen MB, Ank N, Melchjorsen J, Paludan SR.
J Virol. 2010 May;84(9):4579-86. Epub 2010 Feb 24.
Human papillomavirus type 16 E6/E7 upregulation of nucleophosmin is important for proliferation and inhibition of differentiation.
McCloskey R, Menges C, Friedman A, Patel D, McCance DJ.
J Virol. 2010 May;84(10):5131-9. Epub 2010 Mar 17.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on